Skip to main content
Livermore
Livermore
ZHEN

Morgan Stanley

SEC CIK
0000895421
Latest filing
Aug 13, 2026

ELVN holding history

Enliven Therapeutics, Inc. in every 13F filed by Morgan Stanley, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.

ELVN overviewAll 13F holders of ELVNFull Q2 2026 holdings

Shares (Q2 2026)
509,928
Value
$25.9M
% of portfolio
<0.1%
Quarters held
22
Since Q1 2021
Holdings of ELVN by Morgan Stanley, by quarter
QuarterSharesValue% of portfolioShare changeActionAll holders
Q2 2026509,928$25.9M<0.1%−8,644−1.7%ReducedHolders
Q1 2026518,572$20.3M<0.1%+106,749+25.9%AddedHolders
Q4 2025411,823$6.34M<0.1%+153,439+59.4%AddedHolders
Q3 2025258,384$5.29M<0.1%+3,536+1.4%AddedHolders
Q2 2025254,848$5.11M<0.1%+173,533+213.4%AddedHolders
Q1 202581,315$1.60M<0.1%−29,291−26.5%ReducedHolders
Q4 2024110,606$2.49M<0.1%−24,801−18.3%ReducedHolders
Q3 2024135,407$3.46M<0.1%+67,107+98.3%AddedHolders
Q2 202468,300$1.60M<0.1%+5,203+8.2%AddedHolders
Q1 202463,097$1.11M<0.1%−16,424−20.7%ReducedHolders
Q4 202379,521$1.10M<0.1%+45,551+134.1%AddedHolders
Q3 202333,970$464.0K<0.1%+649+1.9%AddedHolders
Q2 202333,321$680.1K<0.1%+15,903+91.3%AddedHolders
Q1 202317,418$381.5K<0.1%−39,330−69.3%ReducedHolders
Q4 202256,748$232.1K<0.1%−4,515−7.4%ReducedHolders
Q3 202261,263$140.0K<0.1%−30,831−33.5%ReducedHolders
Q2 202292,094$112.0K<0.1%−9,840−9.7%ReducedHolders
Q1 2022101,934$191.0K<0.1%−228,847−69.2%ReducedHolders
Q4 2021330,781$744.0K<0.1%+40,133+13.8%AddedHolders
Q3 2021290,648$1.19M<0.1%−138,385−32.3%ReducedHolders
Q2 2021429,033$3.39M<0.1%+106,705+33.1%AddedHolders
Q1 2021322,328$2.72M<0.1%––Holders

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.